Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Tonix Pharmaceuticals Holding stock

Own Tonix Pharmaceuticals Holding stock in just a few minutes.

Tonix Pharmaceuticals Holding Corp is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 26 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Tonix Pharmaceuticals Holding

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TNXP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Tonix Pharmaceuticals Holding share price

Use our graph to track the performance of TNXP stocks over time.

Tonix Pharmaceuticals Holding shares at a glance

Information last updated 2021-04-23.
52-week range$0.51 - $2.12
50-day moving average $1.19
200-day moving average $0.93
Wall St. target price$3.88
PE ratio 0.1372
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.25

Buy Tonix Pharmaceuticals Holding shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tonix Pharmaceuticals Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Tonix Pharmaceuticals Holding under- or over-valued?

Valuing Tonix Pharmaceuticals Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tonix Pharmaceuticals Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Tonix Pharmaceuticals Holding's P/E ratio

Tonix Pharmaceuticals Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Tonix Pharmaceuticals Holding shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Tonix Pharmaceuticals Holding financials

Gross profit TTM $0
Return on assets TTM -56%
Return on equity TTM -103.98%
Profit margin 0%
Book value $0.43
Market capitalisation $335.2 million

TTM: trailing 12 months

Shorting Tonix Pharmaceuticals Holding shares

There are currently 5.6 million Tonix Pharmaceuticals Holding shares held short by investors – that's known as Tonix Pharmaceuticals Holding's "short interest". This figure is 43.9% up from 3.9 million last month.

There are a few different ways that this level of interest in shorting Tonix Pharmaceuticals Holding shares can be evaluated.

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR)

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR) is the quantity of Tonix Pharmaceuticals Holding shares currently shorted divided by the average quantity of Tonix Pharmaceuticals Holding shares traded daily (recently around 22.5 million). Tonix Pharmaceuticals Holding's SIR currently stands at 0.25. In other words for every 100,000 Tonix Pharmaceuticals Holding shares traded daily on the market, roughly 250 shares are currently held short.

However Tonix Pharmaceuticals Holding's short interest can also be evaluated against the total number of Tonix Pharmaceuticals Holding shares, or, against the total number of tradable Tonix Pharmaceuticals Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tonix Pharmaceuticals Holding's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Tonix Pharmaceuticals Holding shares in existence, roughly 20 shares are currently held short) or 0.0174% of the tradable shares (for every 100,000 tradable Tonix Pharmaceuticals Holding shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tonix Pharmaceuticals Holding.

Find out more about how you can short Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding share dividends

We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.

Have Tonix Pharmaceuticals Holding's shares ever split?

Tonix Pharmaceuticals Holding's shares were split on a 1:10 basis on 31 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.

Tonix Pharmaceuticals Holding share price volatility

Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.51 up to $2.12. A popular way to gauge a stock's volatility is its "beta".

TNXP.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 1.3833. This would suggest that Tonix Pharmaceuticals Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Tonix Pharmaceuticals Holding overview

Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site